Integra LifeSciences (NASDAQ:IART) Issues Q2 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its second quarter 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.440-0.520 for the period, compared to the consensus EPS estimate of 0.530. The company issued revenue guidance of $410.0 million-$425.0 million, compared to the consensus revenue estimate of $425.3 million. Integra LifeSciences also updated its FY 2026 guidance to 2.400-2.500 EPS.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $10.65 on Tuesday. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $16.49. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.46 and a current ratio of 2.54. The company has a 50-day simple moving average of $10.09 and a 200 day simple moving average of $11.73. The company has a market capitalization of $830.06 million, a price-to-earnings ratio of -1.58 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The business had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, sell-side analysts predict that Integra LifeSciences will post 2.34 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Wall Street Zen cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Argus reiterated a “hold” rating on shares of Integra LifeSciences in a research note on Wednesday, April 15th. Citigroup dropped their price objective on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating for the company in a research note on Wednesday, March 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Friday, March 27th. Finally, Truist Financial dropped their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $14.20.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bayesian Capital Management LP acquired a new position in shares of Integra LifeSciences in the 2nd quarter valued at approximately $226,000. FORA Capital LLC acquired a new position in shares of Integra LifeSciences in the 2nd quarter valued at approximately $200,000. Envestnet Asset Management Inc. acquired a new position in shares of Integra LifeSciences in the 3rd quarter valued at approximately $190,000. Corient Private Wealth LLC acquired a new position in shares of Integra LifeSciences in the 4th quarter valued at approximately $189,000. Finally, FourThought Financial Partners LLC acquired a new position in shares of Integra LifeSciences in the 3rd quarter valued at approximately $179,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.